1921
Volume 95, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Multidrug-resistant tuberculosis (MDRTB) rates in a human immunodeficiency virus (HIV) care facility increased by the year 2000—56% of TB cases, eight times the national MDRTB rate. We reported the effect of tuberculosis infection control measures that were introduced in 2001 and that consisted of 1) building a respiratory isolation ward with mechanical ventilation, 2) triage segregation of patients, 3) relocation of waiting room to outdoors, 4) rapid sputum smear microscopy, and 5) culture/drug–susceptibility testing with the microscopic-observation drug-susceptibility assay. Records pertaining to patients attending the study site between 1997 and 2004 were reviewed. Six hundred and fifty five HIV/TB–coinfected patients (mean age 33 years, 79% male) who attended the service during the study period were included. After the intervention, MDRTB rates declined to 20% of TB cases by the year 2004 ( = 0.01). Extremely limited access to antiretroviral therapy and specific MDRTB therapy did not change during this period, and concurrently, national MDRTB prevalence increased, implying that the infection control measures caused the fall in MDRTB rates. The infection control measures were estimated to have cost US$91,031 while preventing 97 MDRTB cases, potentially saving US$1,430,026. Thus, this intervention significantly reduced MDRTB within an HIV care facility in this resource-constrained setting and should be cost-effective.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0712
2016-12-07
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/6/1247.html?itemId=/content/journals/10.4269/ajtmh.15-0712&mimeType=html&fmt=ahah

References

  1. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K, , 2007. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196: S86S107.[Crossref]
  2. Andrews JR, Shah NS, Ghandi N, Moll T, Friedland G, , 2007. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 196: S482S490.[Crossref]
  3. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G, , 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 15751580.[Crossref]
  4. Friedland G, Churchyard GJ, Nardell E, , 2007. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 196: S1S3.[Crossref]
  5. Havlir DV, Barnes PF, , 1999. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340: 367373.[Crossref]
  6. Centers for Disease Control and Prevention (CDC), 1996. Multidrug-resistant tuberculosis outbreak on an HIV ward: Madrid, Spain, 1991–1995. Morb Mortal Wkly Rep 45: 330333.
  7. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR, , 1994. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 330: 17101716.[Crossref]
  8. Leonard MK, Egan KB, Kourbatova E, White N, Parrott P, Del Rio C, Blumberg HM, , 2006. Increased efficiency in evaluating patients with suspected tuberculosis by use of a dedicated airborne infection isolation unit. Am J Infect Control 34: 6972.[Crossref]
  9. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA, , 1995. Tuberculosis in New York City: turning the tide. N Engl J Med 333: 229233.[Crossref]
  10. Narvskaya O, Otten T, Limeschenko E, Sapozhnikova N, Graschenkova O, Steklova L, Nikonova A, Filipenko M, Mokrousov I, Vyshnevskiy B, , 2002. Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia. Eur J Clin Microbiol Infect Dis 21: 596602.[Crossref]
  11. Ritacco V, Di Lonardo M, Reniero A, Ambroggi M, Barrera L, Dambrosi A, Lopez B, Isola N, de Kantor IN, , 1997. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 176: 637642.[Crossref]
  12. Ortiz María VG, Ortiz I, Acero E, Gurtman A, , 2004. Prevención de la transmisión nosocomial de tuberculosis. Revista Argentina de Medicina Respiratoria 1: 2329.
  13. Poggio G, Togneri A, Reniero A, Insúa A, Guerra R, Dinerstein E, , 1997. AIDS-related multidrug resistant tuberculosis “M” strain spreads within two hospitals in Buenos Aires suburbs. Int J Tuberc Lung Dis 1: 523.
  14. Campos PE, Suarez PG, Sanchez J, Zavala D, Arevalo J, Ticona E, Nolan CM, Hooton TM, Holmes KK, , 2003. Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons. Peru Emerg Infect Dis 9: 15711578.[Crossref]
  15. Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, Jarvis WR, , 1992. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 117: 191196.[Crossref]
  16. Beck-Sagué C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, Pitchenik AE, Woodley C, Cauthen G, Jarvis WR, , 1992. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 268: 12801286.[Crossref]
  17. Ministerio de Salud del Perú (MINSA), 1995. Actualizacion de las doctrinas, normas y procedimientos para el control de la tuberculosis en el Perú. Lima, Peru: MINSA.
  18. Escombe AR, Moore DA, Gilman RH, Pan W, Navincopa M, Ticona E, Martinez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ, Friedland JS, Evans CA, , 2008. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 5: e188.[Crossref]
  19. Huaroto L, Portaels F, Ticona E, , 1996. La técnica de RFLP en la determinación de patrones epidemiológicos de cepas de M. tuberculosis en personas con SIDA. 9th Congreso Nacional de Medicina Interna. Sociedad Peruana de Medicina Interna, Lima, Peru.
  20. Huaroto L, Portaels F, Ticona E, , 1996. Estudio de la sensibilidad de cepas M. tuberculosis procedentes de pacientes HIV. 9th Congreso Nacional de Medicina Interna. Sociedad Peruana de Medicina Interna, Lima, Peru.
  21. Ticona E, , 1999. Evolución de la Multidrogo resistencia de cepas de M. tuberculosis en pacientes con infección VIH en el Hospital Dos de Mayo de Lima: Perú. 9th Congreso Panamericano de Infectología. Asociación Panamericana de Infectología, Guatemala.
  22. Campos PE, Suarez PG, Sanchez J, Zavala D, Arevalo J, Ticona E, Nolan CM, Hooton TM, Holmes KK, , 2001. Nosocomial outbreak of MDR-TB among HIV patients in Lima, Peru. 32nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Paris, France.
  23. Ministerio de Salud (MINSA) MINSA, 2001. Tuberculosis en el Perú: Informe 2000. , ed. Lima, Peru: Dirección General de Salud de las Personas.
  24. Instituto Nacional de Salud (INS), 2000. Vigilancia de la resistencia a los medicamentos antituberculosos en el Perú, 1999. Lima, Peru: INS.
  25. Centers for Disease Control and Prevention (CDC), 1994. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994, Centers for Disease Control and Prevention. MMWR Recomm Rep 43: 1132.
  26. Escombe AR, Oeser CC, Gilman RH, Navincopa M, Ticona E, Pan W, Martinez C, Chacaltana J, Rodriguez R, Moore DA, Friedland JS, Evans CA, , 2007. Natural ventilation for the prevention of airborne contagion. PLoS Med 4: e68.[Crossref]
  27. Dooley SJ, Castro K, Hutton M, Mullan R, Polder J, Snider DJ, , 1990. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR Recomm Rep 7: 129.
  28. Cookson S, Jarvis W, , 1997. Prevention of nosocomial transmission of Mycobacterium tuberculosis . Infect Dis Clin North Am 11: 385409.[Crossref]
  29. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sanchez E, Sarria M, Becerra M, Smith Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Kim JY, Farmer P, , 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348: 119128.[Crossref]
  30. Rich ML, Socci AR, Mitnick CD, Nardell EA, Becerra MC, Bonilla C, Bayona J, Seung KJ, Furin J, Farmer PE, Mukherjee JS, , 2006. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 10: 290296.
  31. Caviedes L, Lee T-S, Gilman RH, Sheen P, Spellman E, Lee EH, Berg DE, Montenegro-James S, The Tuberculosis Working Group in Peru; , 2000. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. J Clin Microbiol 38: 12031208.
  32. Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J, Vivar A, Sanchez E, Pinedo Y, Saravia JC, Salazar C, Oberhelman R, Hollm-Delgado M-G, LaChira D, Escombe AR, Friedland JS, , 2006. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 355: 15391550.[Crossref]
  33. Resch S, Salomon J, Murray M, Weinstein M, , 2006. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3: e241.[Crossref]
  34. Vásquez L, Asencios L, Quispe N, Díaz S, Carrillo C, Portocarrero J, Suárez P, Canales R, Alarcon E, Yi U, Chu A, Agapito J, Sabogal I, Torres A, , 1997. Vigilancia de la resistencia a los medicamentos antituberculosos en el Peru, 1995–6. Rev Med Exp INS 14: 514.
  35. Asencios L, Quispe N, Mendoza-Ticona A, Leo E, Vásquez L, Jave O, Bonilla C, , 2009. Vigilancia nacional de la resistencia a medicamentos antituberculosis, Perú 2005–2006. Rev Peru Med Exp Salud Publica 26: 278287.
  36. Kawai V, Soto G, Gilman R, Bautista C, Caviedes L, Huaroto L, Ticona E, Ortiz J, Tovar M, Chavez V, Rodriguez R, Escombe A, Evans C, , 2006. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 75: 10271033.
  37. Waisman JL, Palmero DJ, Guemes-Gurtubay JL, Videla JJ, Moretti B, Cantero M, Ambroggi MG, Poggi SE, Sancineto AE, Alberti FA, , 2006. Evaluation of the control measures adopted against an epidemic of AIDS-related multidrug-resistant tuberculosis in a Latin-American hospital [in Spanish]. Enferm Infecc Microbiol Clin 24: 7176.[Crossref]
  38. World Health Organization (WHO), 2009. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. Geneva, Switzerland: WHO.
  39. Tovar MA, Kawai V, Soto G, Benavente J, Sheen P, Ticona E, Gilman RH, Evans CA, , 2013. Multi-drug resistant TB acquisition during clinic-based directly-observed therapy predisposes to adverse patient outcomes. Int J Tuberc Lung Dis 17: S486.[Crossref]
  40. Harries AD, Maher D, Nunn P, , 1997. Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bull World Health Organ 75: 477489.
  41. Pan American Health Organization (PAHO), 2010. Ventilación natural para el control de las infecciones en entornos de asistencia sanitaria. Washington, DC: PAHO.
  42. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, Moodley P, Galvani AP, Friedland GH, , 2007. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370: 15001507.[Crossref]
  43. van Asten L, Langendam M, Zangerle R, Hernandez Aguado I, Boufassa F, Schiffer V, Brettle RP, Robertson JR, Fontanet A, Coutinho RA, Prins M, , 2003. Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drug users with known date of HIV seroconversion. AIDS 17: 12011208.[Crossref]
  44. Antonucci G, Girardi E, Raviglione MC, Ippolito G, , 1995. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 274: 143148.[Crossref]
  45. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S, , 2005. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191: 150158.[Crossref]
  46. Centers for Disease Control and Prevention (CDC), 2005. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. Morb Mortal Wkly Rep 54: 1141.
  47. Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, Lonnroth K, Evans CA, , 2014. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med 11: e1001675.[Crossref]
  48. Escombe AR, Oeser C, Gilman RH, Navincopa M, Ticona E, Martinez C, Caviedes L, Sheen P, Gonzalez A, Noakes C, Moore DA, Friedland JS, Evans CA, , 2007. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis 44: 13491357.[Crossref]
  49. Escombe AR, Moore DAJ, Gilman RH, Navincopa M, Ticona E, Bailey M, Noakes C, Martinez C, Sheen P, Ramirez R, Quino W, Gonzalez A, Friedland JS, Evans CAW, , 2009. Upper-room ultraviolet light and negative ionization to prevent tuberculosis transmission. PLoS Med 6: e1000043.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0712
Loading
/content/journals/10.4269/ajtmh.15-0712
Loading

Data & Media loading...

  • Received : 30 Sep 2015
  • Accepted : 31 Jul 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error